In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
In an interview with ACT editor Andy Studna at SCOPE, Young, Chief Science Officer, CluePoints discusses where the industry is currently adopting RBQM and the level of comfort that comes with it.
CluePoints is dedicated to revolutionizing clinical trials through AI, advanced statistics, and machine learning. Aligned with global regulatory guidance, our holistic risk-based approach is designed to drive positive outcomes. Ready to uncover the clues and pinpoint success in your next trial? Contact our expert team today.
